Answers are grounded in this paper and cite their sources.
Mosquito-transmitted orthoflaviviruses constitute an escalating global threat to public health, for which no approved antiviral therapies exist. Here, we identify the salicylanilide derivative S1 as a West Nile virus (WNV) RNA-dependent RNA-polymerase (RdRp) inhibitor. Chemical optimization of S1 yielded compound S7, which inhibited WNV RdRp activity and displayed antiviral efficacy in Vero cells (EC50 of 3.0 μM; CC50 > 100 μM). S7 and related analogues inhibited Zika virus (ZIKV) RdRp, and this enzymatic inhibition translated into antiviral activity in cell-based assays. Compared with niclosamide, as reference salicylanilide, compound S7 exerted lower impact on mitochondria, reduced cytotoxicity and no induction of apoptosis. Molecular modelling support binding within the polymerase N-pocket, with key contributing residues being highly conserved in both WNV and ZIKV polymerases. Site-directed mutagenesis further supported the importance of N-pocket residues for S7 binding. Therefore, the S7-scaffold constitutes a promising antiviral chemotype against orthoflaviviruses.
No takes yet. Share an insight, caveat, or question.
Río et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: